UBS Group AG Has $110.05 Million Holdings in United Therapeutics Corporation $UTHR

UBS Group AG lifted its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 45.3% in the 4th quarter, Holdings Channel reports. The institutional investor owned 225,849 shares of the biotechnology company’s stock after purchasing an additional 70,445 shares during the quarter. UBS Group AG’s holdings in United Therapeutics were worth $110,045,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. AE Wealth Management LLC increased its holdings in United Therapeutics by 396.3% during the third quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock valued at $1,798,000 after buying an additional 3,424 shares during the period. Great Lakes Advisors LLC grew its holdings in United Therapeutics by 194.7% in the third quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock worth $1,888,000 after purchasing an additional 2,975 shares during the last quarter. Optimize Financial Inc purchased a new position in United Therapeutics in the third quarter worth $444,000. Merit Financial Group LLC grew its holdings in United Therapeutics by 56.3% in the third quarter. Merit Financial Group LLC now owns 7,416 shares of the biotechnology company’s stock worth $3,109,000 after purchasing an additional 2,672 shares during the last quarter. Finally, Tobam grew its holdings in United Therapeutics by 183.9% in the third quarter. Tobam now owns 7,646 shares of the biotechnology company’s stock worth $3,205,000 after purchasing an additional 4,953 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Bank of America lifted their price target on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a report on Tuesday, March 31st. Cantor Fitzgerald lifted their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. Oppenheimer lifted their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Finally, Raymond James Financial began coverage on shares of United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective on the stock. Ten analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $601.50.

Insiders Place Their Bets

In related news, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $470.95, for a total transaction of $10,596,375.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at $9,956,712.48. This represents a 34.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 469,205 shares of company stock valued at $253,860,521 over the last 90 days. 10.30% of the stock is currently owned by insiders.

United Therapeutics Price Performance

Shares of UTHR opened at $570.40 on Friday. The firm has a market capitalization of $25.00 billion, a PE ratio of 20.44, a price-to-earnings-growth ratio of 1.63 and a beta of 0.75. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $607.89. The company’s fifty day moving average price is $543.83 and its 200-day moving average price is $497.42.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The firm had revenue of $790.20 million for the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The business’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same period in the previous year, the company earned $6.19 earnings per share. As a group, research analysts anticipate that United Therapeutics Corporation will post 27.97 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.